[코로나치료제] 일동제약 급락, 이유와 주가는?

일동제약 하락VI가 발동. 전일 대비 15%넘게 하락세

일동제약 31,750 전일대비 하락 5,750 (-15.33%)

2022.01.05. 13:43 장중

• 전일종가37,500
• 고가38,350
• 저가29,150
• 거래량3,988,115
• 외국인소진율3.57%
• 시가 총액7,558억

목		경구용 코로나 치료 후보물질 S-217622 공동개발 및 임상시험(P2/3)에 대한 IND 승인
2. 주요내용		※ 투자유의사항 임상시험 약물이 의약품으로 최종 허가 받을 확률은 통계적으로 약 10% 수준으로 알려져 있습니다. 임상시험 및 품목허가 과정에서 기대에 상응하지 못하 는 결과가 나올 수 있으며, 이에 따라 당사가 상업화 계 획을 변경하거나 포기할 수 있는 가능성도 상존합니다. 투자자는 수시공시 및 사업보고서 등을 통해 공시된 투자 위험을 종합적으로 고려하여 신중히 투자하시기 바 랍니다. 1. 임상시험 제목 - S-217622의 SARS-CoV-2 감염자 대상 제2/3상 시험 (A Phase 2/3 Study of S-217622 in Participants Infected with SARS-CoV-2)

지난 공시내용 이혀 현재 시오노기 홈페이지에 아래 글이 올라오면서

일정이 늦어진다는 것에 대한 투매가 나타남 

Shionogi Announces Commitment to Fight COVID-19

Osaka, Japan, January 5, 2022 - Shionogi & Co., Ltd. (President & CEO: Isao Teshirogi, Ph.D., hereafter: “Shionogi”) has been continuing efforts on an oral antiviral drug and a preventive vaccine for COVID-19. The progress of each of these efforts can be summarized as follows:

 

1.   Commitment to the discovery of novel therapeutic drugs

Regarding an oral antiviral drug (development number: S-217622) that selectively inhibits 3CL protease, enrolment has been completed in the Phase 2a Part of Phase 2/3 clinical trial※ and Phase 2b/3 Part is currently underway. Shionogi has completed the procedures for opening clinical trial sites not only in Japan but also in South Korea, Singapore, Vietnam, etc., and is accelerating patient enrollment. Shionogi will continue discussions with regulatory authorities so that Shionogi can provide this therapeutic drug in Japan and overseas as soon as possible. Regarding supply, Shionogi has already started commercial production, and there is no change in the plan to provide S-217622 for 1 million people by the end of FY2021.

 

※    Phase 2/3 clinical trials consist of Phase 2a and Phase 2b/3 Parts. For details on Phase 2/3 clinical trials, see jRCT2031210350 (https://jrct.niph.go.jp/latest-detail/jRCT2031210350).

 

2.    Commitment to vaccine development

Regarding a preventive vaccine (development number: S-268019), of the four final stage clinical trials, Phase 2/3 clinical trial and an additional dose clinical trial are currently being conducted in Japan, and enrollment of necessary cases and inoculation have already been completed. In addition, of the two remaining clinical trials, a global phase 3 placebo-controlled onset prevention trial was started on December 25, 2021 in Vietnam. Shionogi prepares for another global Phase 3 neutralizing antibody titer comparison trial using an approved vaccine as a control and is scheduled to start in January 2022.

 

Shionogi is committed to “Protect people worldwide from the threat of infectious diseases” as our key focus. We are not only pursuing the research and development of therapeutics, but are also working towards total care for infectious diseases, through awareness building, epidemiologic monitoring, prevention, diagnosis, and addressing exacerbations, as well as the treating the infection itself. As SARS-CoV-2 continues to have a major impact on people’s lives and to represent a global threat, we will seek to contribute to re-establishing the safety and security of society by developing oral therapeutics and preventive vaccine to address this pandemic, and will keep all stakeholders informed regarding the progress of our efforts.

 

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.